Passage Bio out-licenses three pediatric gene therapy programs to GEMMABio, extends cash runway to Q2 2026

Passage BIO, Inc.

Out-licensed PBGM01, PBKR03, PBML04 to GEMMABio; initial $10M + up to $124M milestones + royalties.
Cash of ~$91.8M at June 30, 2024; operating runway extended to end of Q2 2026.
CMO Mark Forman resigned effective Aug 2, 2024; no disagreement with company.
Appointed Susan Browne as CSO and Stuart Henderson as CBO effective Aug 1, 2024.
Entered new collaboration with GEMMABio to advance CNS programs including Huntington's disease.

item 1.01 item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark Forman

Chief Medical Officer

PASG · Passage BIO, Inc.

Effective: 2024-08-02
Filed: August 1, 2024, 7:59 PM ET

On July 26, 2024, Mark Forman, M.D., Ph.D., notified the Company of his decision to resign from his position as the Company’s Chief Medical Officer, effective as of August 2, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Forman resigned as Chief Medical Officer at Passage BIO, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On July 26, 2024, Mark Forman, M.D., Ph.D., notified the Company of his decision to resign from his position as the Company’s Chief Medical Officer, effective as of August 2, 2024.

View on SEC.gov

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-084615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.